Targacept acquires Layton's Inversine
Executive Summary
Targacept (RJ Reynolds Tobacco spin-off exploring nicotinic-based drug targets) has acquired from Layton BioScience (researching neuronal cell therapy and other CNS treatments) its cardiovascular compound Inversine and plans to reformulate it for nervous system disorders.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Product Purchase
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice